CD276 and non-small cell lung carcinoma: The anti-B7-H3 antibody 8H9 (omburtamab) has shown clinical potential in treating central nervous system malignancies and non-small cell lung cancer, which promoted Fc-dependent NK cells through antibody-dependent cell-mediated cytotoxicity (ADCC) function (50, 51).